rigosertib
Trials 38 · a red edge is where a trial was stopped
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 42 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rigosertib | “Rigosertib (ON 01910.Na), a first-in-class Ras mimetic and small-molecule inhibitor of multiple signaling pathways including polo-like kinase 1 (PLK1) and phosphoinositide...” PMID 26091808 ↗ Jun 201521“SyB C-1101 (rigosertib sodium) will be administered to two cohorts of patients; each receives either twice daily (560 mg before breakfast and 560 mg before dinner) or twice...” NCT03495167 ↗ “Rigosertib (ON 01910.Na) is an inhibitor of the phosphoinositide 3-kinase and polo-like kinase pathways that induces mitotic arrest and apoptosis in neoplastic cells, while...” PMID 24777753 ↗ Apr 2014 “SyB L-1101 (rigosertib sodium) will be administered intravenously 72 continuous hours (3 days), followed by 25-day observation period.” NCT02000154 ↗ |
| Known as | Estybon | ChEMBL registry synonym — accepted as the source's own label CHEMBL1241855 ↗ |
| Known as | ON 01910 | “A Phase II Study to Evaluate the Safety and Efficacy of Rigosertib (ON 01910) Plus Pembrolizumab in Patients With Metastatic Melanoma Refractory to Immune Checkpoint Blockade” NCT05764395 ↗ |
| Known as | ON 01910 SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL1241855 ↗ |
| Known as | ON 01910.Na | “We next treated twelve patients with higher risk MDS and two trisomy 8 AML patients with ON 01910.Na on a phase I clinical protocol (NCT00533416).” PMID 22524974 ↗ Apr 201213“One such investigational drug, ON 01910.Na, is a potent and selective inhibitor of the cell cycle and leads to reduction in cyclin D1 expression.” NCT00861510 ↗ |
| Known as | rigosertib sodium | “SyB C-1101 (rigosertib sodium) will be administered to two cohorts of patients; each receives either twice daily (560 mg before breakfast and 560 mg before dinner) or twice...” NCT03495167 ↗7“The primary objective of this study is to determine the largest dose of ON 01910.Na (rigosertib sodium) that can be given safely as a 3-day continuous infusion once every 2...” NCT01538537 ↗ “SyB L-1101 (rigosertib sodium) will be administered intravenously 72 continuous hours (3 days), followed by 25-day observation period.” NCT02000154 ↗ “SyB C-1101（rigosertib sodium） will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period.” NCT02002936 ↗ “SyB L-1101（rigosertib sodium） will be administered to two cohorts at either 1200 mg/day or 1800 mg/day.” NCT01700335 ↗ “SyB C-1101（rigosertib sodium） will be administered to two cohorts at either 280 mg/day or 560 mg/day.” NCT02014051 ↗ “SyB C-1101 (rigosertib sodium)” NCT02783547 ↗ “Drug: rigosertib sodium” NCT01928537 ↗ |
| Known as | SyB C-1101 | “SyB C-1101 (rigosertib sodium) will be administered to two cohorts of patients; each receives either twice daily (560 mg before breakfast and 560 mg before dinner) or twice...” NCT03495167 ↗ |
| Known as | SyB L-1101 | “SyB L-1101 (rigosertib sodium) will be administered intravenously 72 continuous hours (3 days), followed by 25-day observation period.” NCT02000154 ↗ |
| Action | Inhibit | “ON 01910.Na inhibited cyclin D1 expression” PMID 22524974 ↗ Apr 2012 |
| Modality | Small molecule | “preclinical studies using BMMNCs from patients with MDS and AML to examine the effects of the styryl sulfone ON 01910.Na” PMID 22524974 ↗ Apr 2012 |
| Route | Intravenous | “Participants receive ON 01910.Na in 2-week treatment cycles, with 3 to 5 days of drug infusion through a vein” NCT00533416 ↗ |